1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma - Drugs In Development, 2022, provides an overview of the Chondrosarcoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 21, 15, 2 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Chondrosarcoma - Overview
- Chondrosarcoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chondrosarcoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chondrosarcoma - Companies Involved in Therapeutics Development
- Chondrosarcoma - Drug Profiles
- Chondrosarcoma - Dormant Projects
- Chondrosarcoma - Discontinued Products
- Chondrosarcoma - Product Development Milestones
- Featured News & Press Releases
- Aug 15, 2022: European Medicines Agency grants Orphan Drug Designation to INBRX-109 for the treatment of chondrosarcoma
- May 19, 2022: Inhibrx announces details of presentation at 2022 ASCO Annual Meeting
- Feb 28, 2022: Inhibrx selects Genialis ResponderID for clinical optimization study of INBRX-109
- Dec 01, 2021: Inhibrx receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
- Nov 01, 2021: Inhibrx announces participation in upcoming scientific and investor conferences
- Jun 21, 2021: Inhibrx initiates a potential registration-enabling phase 2 study of INBRX-109 in conventional chondrosarcoma patients, updates data for ongoing phase 1 study and announces Amended loan agreement with Oxford
- Jan 13, 2021: Inhibrx granted Fast Track Designation for INBRX-109 for the treatment of unresectable or metastatic conventional chondrosarcoma patients
- Nov 11, 2020: Inhibrx announces positive interim results from the phase 1 trial of INBRX-109 in chondrosarcoma patients
- May 07, 2020: Haihe Pharmaceutical's innovative drug IDH1 inhibitor obtains FDA clinical trial implied permission
- Sep 20, 2019: Bayer highlights new data on Stivarga at ESMO 2019
- Nov 18, 2016: Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Chondrosarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chondrosarcoma - Dormant Projects, 2022
- Chondrosarcoma - Discontinued Products, 2022
- Number of Products under Development for Chondrosarcoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aadi Bioscience Inc
- Acrotech Biopharma LLC
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- Alkermes Plc
- Astex Pharmaceuticals Inc
- Atlanthera
- Bayer AG
- BioAtla Inc
- BioMed Valley Discoveries Inc
- Bristol-Myers Squibb Co
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Eli Lilly and Co
- ENB Therapeutics LLC
- Epeius Biotechnologies Corp
- Epizyme Inc
- Eucure (Beijing) Biopharma Co Ltd
- Horizon Therapeutics Plc
- Hutchison MediPharma Ltd
- Idera Pharmaceuticals Inc
- ImmunityBio Inc
- Incyte Corp
- Inhibrx Inc
- Iovance Biotherapeutics Inc
- Jiangsu Hengrui Medicine Co Ltd
- Karyopharm Therapeutics Inc
- Les Laboratoires Servier SAS
- Merck & Co Inc
- Nanode Therapeutics Inc
- Nerviano Medical Sciences SRL
- NKGen Biotech Inc
- Novartis AG
- Oncorus Inc
- Ono Pharmaceutical Co Ltd
- Pfizer Inc
- Pharma Mar SA
- Rigel Pharmaceuticals Inc
- Shanghai Affinity Biomedical Technology Co Ltd
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Taiho Pharmaceutical Co Ltd
